CAJ | 학술논문

琥珀酸去甲文拉法辛(DVS)是一种5-羟色胺-去甲肾上腺素再摄取抑制剂,是文拉法辛的主要活性代谢物.随机、双盲、安慰剂对照临床研究结果表明,每日1次口服50～400 mg DVS治疗严重抑郁症取得较好疗效,且耐受性较好.最常见的不良反应为短暂的轻到中度恶心.本文对DVS的药动学和药效学特性、临床疗效和药物相互作用以及耐受性等作一综述.
호박산거갑문랍법신(DVS)시일충5-간색알-거갑신상선소재섭취억제제,시문랍법신적주요활성대사물.수궤、쌍맹、안위제대조림상연구결과표명,매일1차구복50～400 mg DVS치료엄중억욱증취득교호료효,차내수성교호.최상견적불량반응위단잠적경도중도악심.본문대DVS적약동학화약효학특성、림상료효화약물상호작용이급내수성등작일종술.
Desvenlafaxine succinate(DVS) is a serotonin-norepinephrine reuptake inhibitor (SNRI). It is the major active metabolite of venlafaxine. In the randomized, double-blind, placebo-controlled trials, DVS is demonstrated to have short-term efficacy for treating major depressive disorder(MDD) with single oral dose ranging from 50-400 mg/d. DVS is well tolerated, the most common treatment-related adverse event is transient nausea that is generally mild to moderate. The pharmacokinetic and pharmacodynamic properties, the clinical efficacy and the drug interactions together with tolerability of DVS in MDD patients are reviewed in this article.